Key Takeaways & Executive Findings
- •• Electronic prescription systems reduce medication errors by up to 50% and improve patient safety. • Successful implementation requires addressing interoperability, cost, and user training challenges. • A phased adoption strategy with stakeholder engagement enhances system acceptance and effectiveness. • Standardized evaluation metrics are needed to assess EPS impact on clinical outcomes and workflow efficiency.
Abstract
Electronic prescription systems (EPS) have emerged as a transformative technology in healthcare, aiming to enhance medication safety, streamline workflows, and reduce errors. This comprehensive review synthesizes current literature on EPS, focusing on implementation challenges, usability, and impact on clinical outcomes. We conducted a systematic search of databases including PubMed, Scopus, and Web of Science, identifying 45 relevant studies. Key findings indicate that EPS significantly reduces prescription errors, improves adherence to formularies, and facilitates better communication among healthcare providers. However, barriers such as high implementation costs, interoperability issues, and resistance from practitioners remain. We propose a framework for successful EPS adoption, emphasizing stakeholder engagement, training, and phased implementation. Our review underscores the need for standardized evaluation metrics and further research on long-term outcomes. This paper provides valuable insights for policymakers, healthcare administrators, and clinicians considering EPS integration.
1. Introduction
Electronic prescription systems (EPS) have revolutionized the way medications are prescribed and managed in healthcare settings. By digitizing the prescription process, EPS aims to eliminate handwritten prescriptions, reduce medication errors, and improve the efficiency of healthcare delivery. The adoption of EPS has been accelerated by government initiatives and technological advancements, yet its implementation is not without challenges.
This review provides a comprehensive analysis of the current state of EPS, examining its benefits, barriers, and best practices for implementation. We explore the impact of EPS on medication safety, workflow efficiency, and patient outcomes, drawing on evidence from diverse healthcare environments. Our goal is to offer a balanced perspective that informs future research and practical adoption strategies.
Loading authentic research manuscript (Pages 1–5)...
Zhang Wei, Li Na, Wang Fang, Chen Yu (2026). Electronic Prescription System: A Comprehensive Review and Implementation Framework. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is an electronic prescription system (EPS)?
An electronic prescription system (EPS) is a digital platform that allows healthcare providers to create, transmit, and manage prescriptions electronically, replacing traditional paper-based methods. It integrates with pharmacy systems and often includes clinical decision support to enhance safety and efficiency.
How does EPS reduce medication errors?
EPS reduces medication errors by eliminating illegible handwriting, providing real-time drug interaction checks, and ensuring accurate dosing through decision support tools. It also facilitates complete medication histories, reducing adverse drug events.
What are the main challenges in implementing EPS?
Key challenges include high initial costs, interoperability issues with existing systems, resistance from healthcare professionals due to workflow changes, and concerns about data privacy and security. Adequate training and stakeholder engagement are critical to overcoming these barriers.
What is the impact of EPS on clinical workflow?
EPS can streamline the prescription process, reduce administrative burden, and improve communication between prescribers and pharmacists. However, it may initially slow down workflows as users adapt, but with proper training, it ultimately enhances efficiency.
What are the future directions for EPS research?
Future research should focus on long-term clinical outcomes, cost-effectiveness, and the integration of EPS with other health information systems. Additionally, exploring patient perspectives and developing standardized evaluation metrics will be essential for optimizing EPS adoption.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.